1.7 USD
-0.05 (-2.86%)
We assign a fundamental rating of 4 out of 10 to TXMD. TXMD was compared to 191 industry peers in the Pharmaceuticals industry. The financial health of TXMD is average, but there are quite some concerns on its profitability. TXMD has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year TXMD was profitable.
In the past year TXMD had a positive cash flow from operations.
In the past 5 years TXMD reported 4 times negative net income.
In the past 5 years TXMD reported 4 times negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of 0.78%, TXMD is doing good in the industry, outperforming 78.53% of the companies in the same industry.
The Return On Equity of TXMD (1.10%) is better than 80.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.78% | ||
| ROE | 1.1% | ||
| ROIC | N/A |
ROA(3y)31.47%
ROA(5y)-21.67%
ROE(3y)92.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TXMD's Profit Margin of 10.80% is amongst the best of the industry. TXMD outperforms 84.29% of its industry peers.
TXMD does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 10.8% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TXMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TXMD remains at a similar level compared to 1 year ago.
Compared to 5 years ago, TXMD has more shares outstanding
TXMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
TXMD has an Altman-Z score of -33.26. This is a bad value and indicates that TXMD is not financially healthy and even has some risk of bankruptcy.
TXMD has a worse Altman-Z score (-33.26) than 90.58% of its industry peers.
There is no outstanding debt for TXMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | -33.26 |
ROIC/WACCN/A
WACC9.43%
2.3 Liquidity
A Current Ratio of 2.93 indicates that TXMD has no problem at all paying its short term obligations.
The Current ratio of TXMD (2.93) is comparable to the rest of the industry.
TXMD has a Quick Ratio of 2.93. This indicates that TXMD is financially healthy and has no problem in meeting its short term obligations.
TXMD has a Quick ratio (2.93) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.93 | ||
| Quick Ratio | 2.93 |
3. Growth
3.1 Past
TXMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 102.21%, which is quite impressive.
TXMD shows a strong growth in Revenue. In the last year, the Revenue has grown by 75.19%.
The Revenue for TXMD have been decreasing by -48.72% on average. This is quite bad
EPS 1Y (TTM)102.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.74%
Revenue 1Y (TTM)75.19%
Revenue growth 3Y-11.84%
Revenue growth 5Y-48.72%
Sales Q2Q%43.33%
3.2 Future
Based on estimates for the next years, TXMD will show a decrease in Earnings Per Share. The EPS will decrease by -8.87% on average per year.
Based on estimates for the next years, TXMD will show a small growth in Revenue. The Revenue will grow by 1.92% on average per year.
EPS Next Y0%
EPS Next 2Y-30.31%
EPS Next 3Y-18.42%
EPS Next 5Y-8.87%
Revenue Next Year1.11%
Revenue Next 2Y1.65%
Revenue Next 3Y1.82%
Revenue Next 5Y1.92%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 170.00, TXMD can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of TXMD indicates a somewhat cheap valuation: TXMD is cheaper than 76.44% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.55. TXMD is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 9.80, which indicates a very decent valuation of TXMD.
TXMD's Price/Forward Earnings ratio is rather cheap when compared to the industry. TXMD is cheaper than 86.91% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.78. TXMD is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 170 | ||
| Fwd PE | 9.8 |
4.2 Price Multiples
TXMD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. TXMD is cheaper than 91.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.51 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as TXMD's earnings are expected to decrease with -18.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-30.31%
EPS Next 3Y-18.42%
5. Dividend
5.1 Amount
TXMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:TXMD (12/15/2025, 8:00:02 PM)
1.7
-0.05 (-2.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners28.6%
Inst Owner Change1.48%
Ins Owners1.55%
Ins Owner Change0%
Market Cap19.67M
Revenue(TTM)2.80M
Net Income(TTM)302.00K
Analysts43.33
Price TargetN/A
Short Float %0.61%
Short Ratio0.25
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 170 | ||
| Fwd PE | 9.8 | ||
| P/S | 7.03 | ||
| P/FCF | 9.51 | ||
| P/OCF | 9.51 | ||
| P/B | 0.72 | ||
| P/tB | 0.84 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.01
EY0.59%
EPS(NY)0.17
Fwd EY10.2%
FCF(TTM)0.18
FCFY10.51%
OCF(TTM)0.18
OCFY10.51%
SpS0.24
BVpS2.37
TBVpS2.03
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.78% | ||
| ROE | 1.1% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 10.8% | ||
| GM | N/A | ||
| FCFM | 73.96% |
ROA(3y)31.47%
ROA(5y)-21.67%
ROE(3y)92.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 684.77% | ||
| Current Ratio | 2.93 | ||
| Quick Ratio | 2.93 | ||
| Altman-Z | -33.26 |
F-Score8
WACC9.43%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)102.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.74%
EPS Next Y0%
EPS Next 2Y-30.31%
EPS Next 3Y-18.42%
EPS Next 5Y-8.87%
Revenue 1Y (TTM)75.19%
Revenue growth 3Y-11.84%
Revenue growth 5Y-48.72%
Sales Q2Q%43.33%
Revenue Next Year1.11%
Revenue Next 2Y1.65%
Revenue Next 3Y1.82%
Revenue Next 5Y1.92%
EBIT growth 1Y45.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y101.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y101.47%
OCF growth 3YN/A
OCF growth 5YN/A
THERAPEUTICSMD INC / TXMD FAQ
What is the ChartMill fundamental rating of THERAPEUTICSMD INC (TXMD) stock?
ChartMill assigns a fundamental rating of 4 / 10 to TXMD.
What is the valuation status for TXMD stock?
ChartMill assigns a valuation rating of 4 / 10 to THERAPEUTICSMD INC (TXMD). This can be considered as Fairly Valued.
What is the profitability of TXMD stock?
THERAPEUTICSMD INC (TXMD) has a profitability rating of 3 / 10.
What is the valuation of THERAPEUTICSMD INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for THERAPEUTICSMD INC (TXMD) is 170 and the Price/Book (PB) ratio is 0.72.
What is the expected EPS growth for THERAPEUTICSMD INC (TXMD) stock?
The Earnings per Share (EPS) of THERAPEUTICSMD INC (TXMD) is expected to decline by 0% in the next year.